Virological Responses
oropharyngeal virus
CORONAVIRUS, VIRUS, SEVERE ACUTE RESPIRATORY SYNDROME
All analytical models of oropharyngeal virus clearance were in excellent agreement. Point estimates and credible intervals (CrIs) were similar, although the nonlinear model gave slightly smaller effect size estimates (Effect of parenteral remdesivir on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral clearance. Left: Median SARS-CoV-2 oropharyngeal virus clearance profiles following remdesivir (darker/grey) and no study drug (lighter/green). Right: estimated treatment effects under the linear model (light with circle) and nonlinear model (dark with triangle). The thick lines show the 80% credible interval (CrI); the thin lines show the 95% CrI.Individual estimate of the viral clearance half-lives with point estimates (squares) and 80% credible intervals (lines). The vertical dashed lines show the median population viral clearance half-lives by treatment arm (lower: no study drug; upper: remdesivir). The median estimated viral clearance half-lives under the linear model were 12.8 (range, 4.8–50.0) hours in the remdesivir arm and 18.0 (range, 3.6–46.7) hours in the contemporaneous control arm.